These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 30036354)

  • 1. Table: drugs for Crohn's disease.
    Med Lett Drugs Ther; 2018 Jul; 60(1550):e115. PubMed ID: 30036354
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug safety in Crohn's disease therapy.
    Juillerat P; Pittet V; Felley C; Mottet C; Froehlich F; Vader JP; Gonvers JJ; Michetti P
    Digestion; 2007; 76(2):161-8. PubMed ID: 18239408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn's disease: a network meta-analysis.
    Hazlewood GS; Rezaie A; Borman M; Panaccione R; Ghosh S; Seow CH; Kuenzig E; Tomlinson G; Siegel CA; Melmed GY; Kaplan GG
    Gastroenterology; 2015 Feb; 148(2):344-54.e5; quiz e14-5. PubMed ID: 25448924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Table: safety of drugs for IBD in pregnancy.
    Med Lett Drugs Ther; 2018 Jul; 60(1550):e116. PubMed ID: 30036355
    [No Abstract]   [Full Text] [Related]  

  • 5. Drugs for inflammatory bowel disease.
    Med Lett Drugs Ther; 2023 Jul; 65(1680):105-112. PubMed ID: 37418329
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparison table: some drugs for inflammatory bowel disease.
    Med Lett Drugs Ther; 2018 Jul; 60(1550):e117-e122. PubMed ID: 30036356
    [No Abstract]   [Full Text] [Related]  

  • 7. Drugs for inflammatory bowel disease.
    Med Lett Drugs Ther; 2018 Jul; 60(1550):107-114. PubMed ID: 30036352
    [No Abstract]   [Full Text] [Related]  

  • 8. Tumor necrosis factor α antagonist-associated psoriasis in inflammatory diseases: an analysis of the FDA adverse event reporting system.
    Kip KE; Swoger JM; Grandinetti LM; Barrie AM; Greer JB; Regueiro MD
    Inflamm Bowel Dis; 2013 May; 19(6):1164-72. PubMed ID: 23518804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Certolizumab pegol: new drug. As a last resort in Crohn's disease: continue to use other TNF alpha inhibitors.
    Prescrire Int; 2009 Jun; 18(101):108-10. PubMed ID: 19637418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expanded table: Some drugs for inflammatory bowel disease.
    Med Lett Drugs Ther; 2023 Jul; 65(1680):e115-e119. PubMed ID: 37418332
    [No Abstract]   [Full Text] [Related]  

  • 11. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
    Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Table: drugs for ulcerative colitis.
    Med Lett Drugs Ther; 2018 Jul; 60(1550):e114. PubMed ID: 30036353
    [No Abstract]   [Full Text] [Related]  

  • 14. [Successful primary infliximab treatment of orofacial Crohn's disease without gastrointestinal manifestation].
    Jung BY; Lee SH; Chung SK; Lee CK; Lee TH; Chung IK; Kim SJ; Cho HD
    Korean J Gastroenterol; 2012 Jun; 59(6):437-40. PubMed ID: 22735878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients.
    Wong DR; Pierik M; Seinen ML; van Bodegraven AA; Gilissen LP; Bus P; Bakker JA; Masclee AA; Neef C; Engels LG; Hooymans PM
    J Crohns Colitis; 2014 Feb; 8(2):120-8. PubMed ID: 23932783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in medical therapy for Crohn's disease.
    D'Haens G; Hlavaty T
    Curr Gastroenterol Rep; 2004 Dec; 6(6):496-505. PubMed ID: 15527680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concomitant therapy with methotrexate and anti-TNF-α in pediatric patients with refractory crohn's colitis: a case series.
    Absah I; Faubion WA
    Inflamm Bowel Dis; 2012 Aug; 18(8):1488-92. PubMed ID: 21882301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful treatment with adalimumab in infliximab-resistant Crohn's disease.
    Barthel HR; Gille T; Halbsguth A; Kramer M
    J Gastroenterol Hepatol; 2005 Sep; 20(9):1464-5. PubMed ID: 16105142
    [No Abstract]   [Full Text] [Related]  

  • 19. Randomized controlled trials in maintenance of remission in Crohn's disease.
    D'Incà R; Caccaro R
    Rev Recent Clin Trials; 2012 Nov; 7(4):270-83. PubMed ID: 23092231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn's disease.
    Walters TD; Kim MO; Denson LA; Griffiths AM; Dubinsky M; Markowitz J; Baldassano R; Crandall W; Rosh J; Pfefferkorn M; Otley A; Heyman MB; LeLeiko N; Baker S; Guthery SL; Evans J; Ziring D; Kellermayer R; Stephens M; Mack D; Oliva-Hemker M; Patel AS; Kirschner B; Moulton D; Cohen S; Kim S; Liu C; Essers J; Kugathasan S; Hyams JS;
    Gastroenterology; 2014 Feb; 146(2):383-91. PubMed ID: 24162032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.